Vitreous Metastasis from Cutaneous Melanoma: Diagnosis and Management
Recommended Citation
Ashkenazy N, Harbour JW, Dubovy SR, Albini TA, Sridhar J, Patel N, Hansen ED, Uchiyama E, Rubsamen PE, and Correa ZM. Vitreous metastasis from cutaneous melanoma: diagnosis and management. Arq Bras Oftalmol 2024; 87(5).
Document Type
Article
Publication Date
2024
Publication Title
Arq Bras Oftalmol
Abstract
Purpose: To report the clinical findings, treatments, and outcomes in a series of patients with vitreous metastasis from cutaneous melanoma.
Methods: This single-center, retrospective, interventional case series included patients with biopsy-confirmed vitreous metastasis from cutaneous melanoma diagnosed between 1997 and 2020. Standard 23- or 25-gauge pars plana vitrectomy was performed for diagnostic sampling. Sclerotomies were treated with double or triple freeze-thaw cryotherapy. Perioperative intravitreal injections of melphalan (32 μg/0.075 mL) were administered, when indicated. Visual acuity, intraocular pressure, and systemic and ocular treatment responses were reported.
Results: Five eyes of five patients with unilateral vitreous metastasis from cutaneous melanoma were identified. The median age at diagnosis was 84 (range, 37–88) years. The median follow-up after ophthalmic diagnosis was 28 (8.5-36) months; one patient did not have a follow-up. The initial visual acuity ranged from 20/30 to hand motions. Baseline clinical findings included pigmented or non-pigmented cellular infiltration of the vitreous (5/5), anterior segment (4/5), and retina (3/5). Four patients had secondary glaucoma. Systemic therapy included checkpoint inhibitor immunotherapy (n=3, all with partial/complete response), systemic chemotherapy (n=2), surgical resection (n=3), and radiation (n=2). The median time from primary diagnosis to vitreous metastasis was 2 (2–15) years. One patient had an active systemic disease at the time of vitreous metastasis. The final visual acuity ranged from 20/40 to no light perception. Ophthalmic treatment included vitrectomy in all five patients, intravitreal administration of melphalan in three, and intravitreal administration of methotrexate in one. One patient required enucleation, and histopathology revealed extensive invasion by melanoma cells.
Conclusions: Vitreous metastasis from cutaneous melanoma can present as a diffuse infiltration of pigmented or non-pigmented cells into the vitreous and may be misdiagnosed as uveitis. Diagnostic pars plana vitrectomy and periodic intravitreal chemotherapy may be indicated.
ePublication
ePub ahead of print
Volume
87
Issue
5
Last Page
http://sfxhosted.exlibrisgroup.com/hfhs?sid=EMBASE&issn=16782925&id=doi:10.5935%2F0004-2749.2022-0215&atitle=Vitreous+metastasis+from+cutaneous+melanoma%3A+diagnosis+and+management&stitle=Arq.+Bras.+Oftalmol.&title=Arquivos+Brasileiros+de+Oftalmologia&volume=87&issue=5&spage=&epage=&aulast=Ashkenazy&aufirst=Noy&auinit=N.&aufull=Ashkenazy+N.&coden=AQBOA&isbn=&pages=-&date=2024&auinit1=N&auinitm=
